Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Current Assets: 2016-2025

Historic Current Assets for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Sep 2025 value amounting to $227.7 million.

  • Rocket Pharmaceuticals' Current Assets fell 5.82% to $227.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $227.7 million, marking a year-over-year decrease of 5.82%. This contributed to the annual value of $378.2 million for FY2024, which is 0.01% down from last year.
  • As of Q3 2025, Rocket Pharmaceuticals' Current Assets stood at $227.7 million, which was down 17.85% from $277.2 million recorded in Q2 2025.
  • Rocket Pharmaceuticals' Current Assets' 5-year high stood at $471.8 million during Q1 2021, with a 5-year trough of $227.7 million in Q3 2025.
  • For the 3-year period, Rocket Pharmaceuticals' Current Assets averaged around $323.8 million, with its median value being $324.5 million (2025).
  • As far as peak fluctuations go, Rocket Pharmaceuticals' Current Assets soared by 82.27% in 2021, and later crashed by 45.90% in 2024.
  • Rocket Pharmaceuticals' Current Assets (Quarterly) stood at $392.1 million in 2021, then decreased by 7.14% to $364.1 million in 2022, then increased by 3.89% to $378.2 million in 2023, then dropped by 0.01% to $378.2 million in 2024, then dropped by 5.82% to $227.7 million in 2025.
  • Its Current Assets stands at $227.7 million for Q3 2025, versus $277.2 million for Q2 2025 and $324.5 million for Q1 2025.